Global China FeNO Testing Market Size, Share, Growth Analysis Report - Forecast 2034

China FeNO Testing Market: Industry Perspective

The global China feno testing market size was worth around USD 29.56 Million in 2024 and is predicted to grow to around USD 101.97 Million by 2034 with a compound annual growth rate (CAGR) of roughly 13.18% between 2025 and 2034. The report analyzes the global China feno testing market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the China feno testing industry.

Request Free Sample

China FeNo Testing Market: Overview

FeNo stands for Fractional Exhaled Nitric Oxide. It is a medical term that is used to refer to the process of measuring nitric oxide (NO) levels in a person’s exhaled breath. NO is a gas that is produced by cells that exist in the lining of the airways. FeNO measurements can help in gaining more insights into the inflammation of the airway. When spoken in the context of respiratory health, FeNO testing is commonly used during the diagnosis, monitoring, and management of asthma which is a chronic respiratory condition that is characterized by inflammation and narrowing of the airways. During the testing process, the level of exhaled nitric oxide provides information on airway inflammation, particularly eosinophilic inflammation, which typically means that the person has contracted asthma. The industry deals with the economic and infrastructural aspects of FeNO testing across the Chinese province.

Key Insights

• As per the analysis shared by our research analyst, the global China feno testing market is estimated to grow annually at a CAGR of around 13.18% over the forecast period (2025-2034).
• Regarding revenue, the global China feno testing market size was valued at around USD 29.56 Million in 2024 and is projected to reach USD 101.97 Million by 2034.
• The China feno testing market is projected to grow at a significant rate due to rising prevalence of respiratory diseases, increasing adoption of non-invasive diagnostic tools, growing healthcare investments, and advancements in asthma and COPD management technologies.
• Based on Type, the Nitric Oxide Handheld Monitor segment is expected to lead the global market.
• On the basis of Indication, the Eosinophilic Airway Inflammation segment is growing at a high rate and will continue to dominate the global market.
• Based on the End User, the Hospitals segment is projected to swipe the largest market share.
• By Distribution Channel, the Direct Tender segment is expected to dominate the global market.
• Based on region, Asia-Pacific is predicted to dominate the global market during the forecast period.

China FeNO Testing Market: Dynamics

Key Growth Drivers:

The China FeNO testing market is primarily driven by the increasing prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and allergic airway disorders. Growing awareness among healthcare professionals and patients about the benefits of fractional exhaled nitric oxide (FeNO) testing for accurate and non-invasive respiratory assessment is significantly boosting market demand. Government initiatives aimed at improving diagnostic accuracy and expanding healthcare infrastructure are also supporting growth. Moreover, advancements in FeNO testing devices, including portable and easy-to-use models suitable for clinical and home-based applications, are further propelling market expansion.

Restraints:

Despite its growth potential, the China FeNO testing market faces certain restraints such as the high cost of advanced FeNO analyzers and limited reimbursement coverage for respiratory diagnostic procedures. The lack of awareness in rural areas and limited access to trained healthcare professionals for accurate interpretation of FeNO results also hinder widespread adoption. Additionally, competition from traditional diagnostic methods, such as spirometry, which are more affordable and widely available, poses a challenge to the broader use of FeNO testing in routine respiratory care.

Opportunities:

The growing focus on early diagnosis and personalized treatment of respiratory diseases in China offers promising opportunities for the FeNO testing market. Increasing investments in digital healthcare technologies and the integration of FeNO devices with mobile health (mHealth) applications can enhance remote monitoring and disease management. Expanding healthcare coverage in tier 2 and tier 3 cities, along with the rising demand for home-based respiratory care solutions, further opens new avenues for market players. Additionally, partnerships between local healthcare providers and international diagnostic device manufacturers can foster innovation and accelerate the availability of advanced FeNO testing systems across the country.

Challenges:

The China FeNO testing market faces challenges related to stringent regulatory approvals and varying quality standards for diagnostic devices. Limited awareness about FeNO testing among general practitioners and patients may slow down its adoption rate, particularly outside major urban centers. Furthermore, the need for continuous device calibration and maintenance can increase operational costs for healthcare facilities. Intense market competition and the pressure to offer affordable solutions without compromising accuracy also pose difficulties for manufacturers aiming to sustain profitability in a rapidly evolving healthcare environment.

Request Free Sample

China FeNo Testing Market: Segmentation

The China FeNo testing market is segmented based on indication, type, distribution channel, end-user, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2025 to 2034.

Based on indication, the regional market is divided into chronic respiratory symptoms, eosinophilic airway inflammation, COPD with mixed inflammatory phenotype, atopic asthma, cystic fibrosis, pulmonary arterial hypertension, eosinophilic bronchitis, corticosteroid responsiveness, and others. The China FeNo testing industry witnessed the highest growth in the chronic respiratory symptoms segment, Asthma is typically characterized by frequent episodes of chronic respiratory symptoms. These symptoms tend to vary in intensity between patients. Eosinophilic airway inflammation is a very specific type of inflammation and occurs in the airways of individuals with certain respiratory conditions and one of them is asthma. Chronic obstructive pulmonary disease (COPD) with a mixed inflammatory phenotype is COPD characterized by the presence of both eosinophilic and neutrophilic inflammation in the airways. In recent times, China’s commercial health insurance premium income grew by 30%.

Based on type, the global market divisions are Nitric Oxide standalone monitors, nitric oxide handheld monitors, and others.

Based on distribution channel, the global market segments are retail sales, direct tender, and online sales. The China FeNo testing industry witnessed the highest growth in the direct tender segment in 2024 due to the majority of the hospitals collaborating with suppliers and manufacturers of FeNo testing kits. However, the online sales segment is expected to grow at a higher CAGR during the forecast period as compared to previous years due to the growing popularity of online sales in the healthcare sector. In recent times, China has registered surging growth in e-commerce and online platforms which also includes the sale of medical devices and diagnostics. There are several advantages associated with online purchases. During the projection period, factors such as convenience, accessibility, and growing digital infrastructure are projected to play a crucial role in segmental growth. 

China FeNo Testing Market: Report Scope

China FeNo Testing Market: Regional Analysis

China to witness a high growth rate during the forecast period

The China FeNo testing market is projected to grow rapidly owing to the increasing number of asthmatic patients in the Chinese province. Factors such as increased rates of air pollution and other environmental factors are leading causes of the rise in the asthmatic population. In addition to this, the Chinese chemical industry, which is also one of the world’s most dominant chemical industries, has resulted in addition to the already bad quality of air in this region. The highest growth rate may be observed in the Tier 1 cities of China. This includes regions such as Beijing, Shanghai, Guangzhou, and Shenzhen. The higher growth rate could be a result of the existence of a well-developed healthcare infrastructure and a higher concentration of specialized healthcare facilities. This segment is expected to provide more FeNo testing measures.

China FeNO Testing Market: Competitive Analysis

The report provides a company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the China feno testing market on a global and regional basis.

The global China feno testing market is dominated by players like:

• Guangzhou Kingmed Diagnostics Group Co. Ltd.
• Hangzhou Clongene Biotech Co. Ltd.
• Shanghai Fosun Long March Medical Science Co. Ltd.
• Nanjing Norman Biological Technology Co. Ltd.
• Beijing Eastwest Harmony Medical Devices Co. Ltd.
• Guangzhou YERCON Diagnostic Co. Ltd.
• Aeonmed Co. Ltd.
• Haina Bio-Medical Technology Co. Ltd.
• Shanghai Hua An Medical Health Science Co. Ltd.
• Wuxi Medical Instrument Factory Co. Ltd.
• Shanghai Hengkang Medical Equipment Co. Ltd.
• Mindray Medical International Limited
• Nihon Kohden Corporation
• Edan Instruments Inc.
• Shenzhen Comen Medical Instruments Co. Ltd.
• Yuyue Medical Equipment & Supply Co. Ltd.
• Biolight Meditech Co. Ltd.
• Perlong Medical Equipment Co. Ltd.
• Beijing Choice Electronic Technology Co. Ltd.
• M&B Electronic Instruments Inc.
• Shenzhen Creative Industry Co. Ltd.
• Chindex Medical Limited
• Yantai Dongcheng Biochemicals Co. Ltd.
• Jiangsu Yuyue Medical Equipment & Supply Co. Ltd.
• Shenzhen Anke High-tech Co. Ltd.

The China FeNo testing market is segmented as follows:

By Indication

• Chronic Respiratory Symptoms
• Eosinophilic Airway Inflammation
• COPD with Mixed Inflammatory Phenotype
• Atopic Asthma
• Cystic Fibrosis
• Pulmonary Arterial Hypertension
• Eosinophilic Bronchitis
• Corticosteroid Responsiveness
• Others

By Type

• Nitric Oxide Standalone Monitor
• Nitric Oxide Handheld Monitor
• Others

By Distribution Channel

• Retail Sales
• Direct Tender
• Online Sales

By Region

• China